Has Stavros Drakos, MD received payments from drug or device companies?

Yes. Drug and device makers reported $78,676 in general payments to Stavros Drakos, MD across 158 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stavros Drakos, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stavros Drakos, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stavros Drakos, MD

Interventional Cardiology · Salt Lake City, UTNPI 1457627192

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $57,005 of the $78,676 with a category attached, or 72.5%. Abbott accounts for 97.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $49,763, more than ten times the $4,298 reported in 2019. Among interventional cardiology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,676in general payments, 2019–2025

Across 158 payments — averaging $497.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$76K
Abiomed$2K
Medtronic$129
Cvrx, Inc.$122
Novo Nordisk$88
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$39

$494,851in research payments, 2019–2025

Across 13 payments — averaging $38,065 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$450K
Abbott$43K
Cvrx, Inc.$2K

What the payments were for

Consulting fees$57,00572%
Speaking & faculty fees$2,7503%
Travel & lodging$13,33017%
Food & beverage$5,5917%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	135	$76,432
Abiomed	16	$1,866
Medtronic(2 entities)	3	$129
Cvrx, Inc.	1	$122
Novo Nordisk	1	$88
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

THORATEC HEARTMATE 3 LVAS IMPLANT KIT$54,733
CARDIOMEMS$13,401
CardioMEMS HF System$3,785
Impella$1,447
2ND GEN CENTRIMAG PRIMARY CONSOLE$1,120
HeartMate Touch$645
FreeStyle Libre Pro$325
Trifecta GT Tissue Heart Valve$263
THORATEC HEARTMATE II, LVAS IMPLANT KIT$134
Barostim Neo System$122
HeartMate 3 Left Ventricular Assist Device$116

How this compares

$78,676 in reported general payments places this provider in the 90th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah →

Medicare billing

Part B allowed, 2024

$15,789

Medicare patients

Services billed

144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EntrestoSacubitril/Valsartan	11	$12,614
FarxigaDapagliflozin Propanediol	11	$6,268
Digoxin	11	$453
Isosorbide Mononitrate ErIsosorbide Mononitrate	12	$167
Carvedilol	18	$162
Omeprazole	11	$121
Spironolactone	11	$82
Sodium Chloride0.9 % Sodium Chloride	12	$25

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Salt Lake City

Vamsee YagantiSalt Lake City$390K
Anwar TandarSalt Lake City$131K
Frederick WeltSalt Lake City$26K
Scott HackingSalt Lake City$22K
Eric LindleySalt Lake City$18K
Lee LinstrothSalt Lake City$14K
Theophilus OwanSalt Lake City$9K
Diana MeloSalt Lake City$4K
Tara JonesSalt Lake City$4K
Scott BrewsterSalt Lake City$4K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →